GlobeNewswire·Nov 10, 2026, 4:15 PM ET

Spectral AI Announces 2026 Third Quarter Financial Results

Spectral AI expects the first U.S. commercial placement of its DeepView AI System in Q4 2026 with initial deliveries scheduled by year-end.
The company is manufacturing the first 30 DeepView AI Systems for BARDA-supported deployment at U.S. burn centers.
Q3 2026 operating expenses decreased by 4.4% to $4.7 million while research and development revenue fell 24.7% to $2.9 million.
Cash & cash equivalents stood at $11.2 million at September 30, 2026, down from $15.4 million at December 31, 2025.
Net loss for Q3 2026 was $3.7 million, or $0.11 per share, compared to a $3.6 million loss in the prior year period.
The company submitted a New Technology Add-On Payment application to CMS for DeepView AI reimbursement with a decision expected by August 2027.
Clinical study site initiation visits were completed at four U.K. burn centers, with ten patients enrolled for label expansion to head, hands, & feet burns.
2026 research & development revenue guidance was lowered to approximately $13.0 million from $18.5 million due to the completion of the MTEC program.
Selling & marketing expenses increased 12.8% to $0.4 million to support commercialization activities ahead of the product launch.
General & administrative expenses dropped to $2.3 million primarily due to reduced legal fees & related professional services.